tiprankstipranks
Biontech Se Sponsored Adr (GB:0A3M)
NASDAQ:0A3M
UK Market
0A3M
BioNTech SE
RESEARCH TOOLSreports

BioNTech SE (0A3M) Share Forecast & Price Target

6 Followers
See the Price Targets and Ratings of:

0A3M Analyst Ratings

Strong Buy
13Ratings
Strong Buy
11 Buy
2 Hold
0 Sell
Based on 13 analysts giving stock ratings to
BioNTech
SE
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0A3M Stock 12 Month Forecast

Average Price Target

$128.58
▲(43.14% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for BioNTech SE in the last 3 months. The average price target is $128.58 with a high forecast of $142.00 and a low forecast of $96.00. The average price target represents a 43.14% change from the last price of $89.83.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"89":"$89","116":"$116","143":"$143","102.5":"$102.5","129.5":"$129.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":142,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$142.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":128.58333333333331,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$128.58</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":96,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$96.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[89,102.5,116,129.5,143],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,91.11,95.02461538461539,98.93923076923078,102.85384615384615,106.76846153846154,110.68307692307692,114.59769230769231,118.5123076923077,122.42692307692307,126.34153846153846,130.25615384615384,134.17076923076922,138.0853846153846,{"y":142,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,91.11,93.9925641025641,96.8751282051282,99.75769230769231,102.6402564102564,105.5228205128205,108.4053846153846,111.28794871794871,114.17051282051281,117.0530769230769,119.93564102564102,122.81820512820511,125.70076923076921,{"y":128.58333333333331,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,91.11,91.48615384615384,91.8623076923077,92.23846153846154,92.61461538461539,92.99076923076923,93.36692307692307,93.74307692307693,94.11923076923077,94.49538461538461,94.87153846153846,95.2476923076923,95.62384615384616,{"y":96,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":106.556,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.437,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.762,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.945,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.899,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.06,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.52,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.84,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.146,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.04,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.04,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.05,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.11,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$142.00Average Price Target$128.58Lowest Price Target$96.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BMO Capital Analyst forecast on GB:0A3M
Evan Seigerman
BMO Capital
BMO Capital
$128
Buy
42.49%
Upside
Reiterated
08/28/26
Cevumeran trial termination a 'clear setback' for BioNTech, says BMO CapitalCevumeran trial termination a 'clear setback' for BioNTech, says BMO Capital
Deutsche Bank Analyst forecast on GB:0A3M
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
$140
Buy
55.85%
Upside
Reiterated
08/26/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Morgan Stanley Analyst forecast on GB:0A3M
Terence Flynn
Morgan Stanley
Morgan Stanley
$115
Buy
28.02%
Upside
Assigned
08/24/26
Morgan Stanley Releases a Buy Rating on BioNTech SE (BNTX)
Jefferies Analyst forecast on GB:0A3M
Akash Tewari
Jefferies
Jefferies
$138
Buy
53.62%
Upside
Reiterated
08/20/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: BioNTech SE (NASDAQ: BNTX) and Centene (NYSE: CNC)
Canaccord Genuity Analyst forecast on GB:0A3M
John Newman
Canaccord Genuity
Canaccord Genuity
$142
Buy
58.08%
Upside
Reiterated
08/20/26
Analysts Offer Insights on Healthcare Companies: BioNTech SE (NASDAQ: BNTX) and DocGo (NASDAQ: DCGO)
Wells Fargo Analyst forecast on GB:0A3M
Mohit Bansal
Wells Fargo
Wells Fargo
$140
Buy
55.85%
Upside
Reiterated
08/19/26
Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (NASDAQ: XERS) and BioNTech SE (NASDAQ: BNTX)
J.P. Morgan Analyst forecast on GB:0A3M
Jessica Fye
J.P. Morgan
J.P. Morgan
―
Hold
―
Reiterated
08/19/26
BioNTech: Cash-Rich Oncology Pipeline Supports Sentiment, But Clinical and Valuation Uncertainties Warrant Hold Rating
Evercore ISI Analyst forecast on GB:0A3M
Cory Kasimov
Evercore ISI
Evercore ISI
$135→$130
Buy
44.72%
Upside
Reiterated
08/05/26
BioNTech price target lowered to $130 from $135 at Evercore ISIBioNTech price target lowered to $130 from $135 at Evercore ISI
Citi Analyst forecast on GB:0A3M
Geoff Meacham
Citi
Citi
$130→$125
Buy
39.15%
Upside
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (NASDAQ: PCRX), BioNTech SE (NASDAQ: BNTX) and Henry Schein (NASDAQ: HSIC)
Berenberg Bank Analyst forecast on GB:0A3M
Harry Gillis
Berenberg Bank
Berenberg Bank
$140→$132
Buy
46.94%
Upside
Reiterated
08/05/26
Analysts Are Bullish on Top Healthcare Stocks: BioNTech SE (BNTX), Pfizer (PFE)
Bank of America Securities Analyst forecast on GB:0A3M
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$125→$122
Buy
35.81%
Upside
Reiterated
08/04/26
BioNTech: New Leadership and Advancing Oncology Pipeline Underpin Buy Rating Despite Lowered Price Target to $122
UBS Analyst forecast on GB:0A3M
David Dai
UBS
UBS
$135
Buy
50.28%
Upside
Reiterated
08/04/26
BioNTech: Oncology Pipeline, Strong Leadership, and Cash Balance Support Buy Rating with Unchanged $135 Price Target
Bernstein Analyst forecast on GB:0A3M
Jeffrey Walch
Bernstein
Bernstein
$96
Hold
6.87%
Upside
Reiterated
08/04/26
Bernstein Sticks to Their Hold Rating for BioNTech SE (BNTX)
TD Cowen Analyst forecast on GB:0A3M
Yaron Werber
TD Cowen
TD Cowen
$94
Hold
4.64%
Upside
Reiterated
05/05/26
Analysts Offer Insights on Healthcare Companies: Orthofix Medical (NASDAQ: OFIX), BioNTech SE (NASDAQ: BNTX) and Cogent Biosciences (NASDAQ: COGT)
Goldman Sachs Analyst forecast on GB:0A3M
Asad Haider
Goldman Sachs
Goldman Sachs
$132→$133
Buy
48.06%
Upside
Reiterated
05/05/26
BioNTech SE (BNTX) Receives a Buy from Goldman Sachs
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BMO Capital Analyst forecast on GB:0A3M
Evan Seigerman
BMO Capital
BMO Capital
$128
Buy
42.49%
Upside
Reiterated
08/28/26
Cevumeran trial termination a 'clear setback' for BioNTech, says BMO CapitalCevumeran trial termination a 'clear setback' for BioNTech, says BMO Capital
Deutsche Bank Analyst forecast on GB:0A3M
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
$140
Buy
55.85%
Upside
Reiterated
08/26/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Morgan Stanley Analyst forecast on GB:0A3M
Terence Flynn
Morgan Stanley
Morgan Stanley
$115
Buy
28.02%
Upside
Assigned
08/24/26
Morgan Stanley Releases a Buy Rating on BioNTech SE (BNTX)
Jefferies Analyst forecast on GB:0A3M
Akash Tewari
Jefferies
Jefferies
$138
Buy
53.62%
Upside
Reiterated
08/20/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: BioNTech SE (NASDAQ: BNTX) and Centene (NYSE: CNC)
Canaccord Genuity Analyst forecast on GB:0A3M
John Newman
Canaccord Genuity
Canaccord Genuity
$142
Buy
58.08%
Upside
Reiterated
08/20/26
Analysts Offer Insights on Healthcare Companies: BioNTech SE (NASDAQ: BNTX) and DocGo (NASDAQ: DCGO)
Wells Fargo Analyst forecast on GB:0A3M
Mohit Bansal
Wells Fargo
Wells Fargo
$140
Buy
55.85%
Upside
Reiterated
08/19/26
Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (NASDAQ: XERS) and BioNTech SE (NASDAQ: BNTX)
J.P. Morgan Analyst forecast on GB:0A3M
Jessica Fye
J.P. Morgan
J.P. Morgan
―
Hold
―
Reiterated
08/19/26
BioNTech: Cash-Rich Oncology Pipeline Supports Sentiment, But Clinical and Valuation Uncertainties Warrant Hold Rating
Evercore ISI Analyst forecast on GB:0A3M
Cory Kasimov
Evercore ISI
Evercore ISI
$135→$130
Buy
44.72%
Upside
Reiterated
08/05/26
BioNTech price target lowered to $130 from $135 at Evercore ISIBioNTech price target lowered to $130 from $135 at Evercore ISI
Citi Analyst forecast on GB:0A3M
Geoff Meacham
Citi
Citi
$130→$125
Buy
39.15%
Upside
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (NASDAQ: PCRX), BioNTech SE (NASDAQ: BNTX) and Henry Schein (NASDAQ: HSIC)
Berenberg Bank Analyst forecast on GB:0A3M
Harry Gillis
Berenberg Bank
Berenberg Bank
$140→$132
Buy
46.94%
Upside
Reiterated
08/05/26
Analysts Are Bullish on Top Healthcare Stocks: BioNTech SE (BNTX), Pfizer (PFE)
Bank of America Securities Analyst forecast on GB:0A3M
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$125→$122
Buy
35.81%
Upside
Reiterated
08/04/26
BioNTech: New Leadership and Advancing Oncology Pipeline Underpin Buy Rating Despite Lowered Price Target to $122
UBS Analyst forecast on GB:0A3M
David Dai
UBS
UBS
$135
Buy
50.28%
Upside
Reiterated
08/04/26
BioNTech: Oncology Pipeline, Strong Leadership, and Cash Balance Support Buy Rating with Unchanged $135 Price Target
Bernstein Analyst forecast on GB:0A3M
Jeffrey Walch
Bernstein
Bernstein
$96
Hold
6.87%
Upside
Reiterated
08/04/26
Bernstein Sticks to Their Hold Rating for BioNTech SE (BNTX)
TD Cowen Analyst forecast on GB:0A3M
Yaron Werber
TD Cowen
TD Cowen
$94
Hold
4.64%
Upside
Reiterated
05/05/26
Analysts Offer Insights on Healthcare Companies: Orthofix Medical (NASDAQ: OFIX), BioNTech SE (NASDAQ: BNTX) and Cogent Biosciences (NASDAQ: COGT)
Goldman Sachs Analyst forecast on GB:0A3M
Asad Haider
Goldman Sachs
Goldman Sachs
$132→$133
Buy
48.06%
Upside
Reiterated
05/05/26
BioNTech SE (BNTX) Receives a Buy from Goldman Sachs
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ODTXOdyssey Therapeutics, Inc.
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BioNTech SE

3 Months
John NewmanCanaccord Genuity
Success Rate
10/14 ratings generated profit
71%
Average Return
+8.04%
Copying John Newman's trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +8.04% per trade.
1 Year
Robert BurnsH.C. Wainwright
Success Rate
16/23 ratings generated profit
70%
Average Return
+6.52%
Copying Robert Burns's trades and holding each position for 1 Year would result in 69.57% of your transactions generating a profit, with an average return of +6.52% per trade.
2 Years
Akash TewariJefferies
Success Rate
11/14 ratings generated profit
79%
Average Return
+64.63%
Copying Akash Tewari's trades and holding each position for 2 Years would result in 78.57% of your transactions generating a profit, with an average return of +64.63% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0A3M Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
9
14
9
8
6
Buy
16
19
12
10
18
Hold
3
5
6
5
5
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
28
38
27
23
29
In the current month, 0A3M has received 24 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. 0A3M average Analyst price target in the past 3 months is 128.58.
Each month's total comprises the sum of three months' worth of ratings.

0A3M Financial Forecast

0A3M Earnings Forecast

Next quarter’s earnings estimate for 0A3M is $0.86 with a range of -$0.02 to $1.59. The previous quarter’s EPS was -$3.78. 0A3M beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0A3M has Performed in-line its overall industry.
Next quarter’s earnings estimate for 0A3M is $0.86 with a range of -$0.02 to $1.59. The previous quarter’s EPS was -$3.78. 0A3M beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0A3M has Performed in-line its overall industry.

0A3M Sales Forecast

Next quarter’s sales forecast for 0A3M is $1.24B with a range of $991.49M to $1.41B. The previous quarter’s sales results were $122.78M. 0A3M beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0A3M has Performed in-line its overall industry.
Next quarter’s sales forecast for 0A3M is $1.24B with a range of $991.49M to $1.41B. The previous quarter’s sales results were $122.78M. 0A3M beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0A3M has Performed in-line its overall industry.

0A3M Stock Forecast FAQ

What is GB:0A3M’s average 12-month price target, according to analysts?
Based on analyst ratings, Biontech Se Sponsored Adr’s 12-month average price target is 128.58.
    What is GB:0A3M’s upside potential, based on the analysts’ average price target?
    Biontech Se Sponsored Adr has 43.14% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Biontech Se Sponsored Adr a Buy, Sell or Hold?
          Biontech Se Sponsored Adr has a consensus rating of Strong Buy, which is based on 11 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Biontech Se Sponsored Adr’s share price target?
            The average share price target for Biontech Se Sponsored Adr is 128.58. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $142.00 ,and the lowest forecast is $96.00. The average share price target represents 43.14% Increase from the current price of $89.83.
              What do analysts say about Biontech Se Sponsored Adr?
              Biontech Se Sponsored Adr’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of Biontech Se Sponsored Adr?
                To buy shares of GB:0A3M, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.